Study design and treatment schedule. The treatment is separated into an induction phase with the triple combination of obinutuzumab, venetoclax, and ibrutinib; a consolidation phase with ibrutinib/venetoclax, 6 cycles each; and a maintenance phase with ibrutinib monotherapy according to response (MRD at cycle 9, 12, 15; CT scan at cycle 12; BM biopsy during cycle 14/at cycle 15). In case of MRD negativity at cycles 9 and 12 and confirmed CR/CRi at final restaging, ibrutinib is stopped.